DC Judge Calls Teva's Bid To Reclassify Drug Anticompetitive

By Julia Arciga (January 4, 2021, 10:26 PM EST) -- A D.C. federal court has shot down Teva Pharmaceutical's lawsuit against the U.S. Food and Drug Administration and the Department of Health and Human Services to get its multiple sclerosis drug Copaxone reclassified from a "drug" to a "biological product," calling the suit "yet another effort" by the company to "stifle Copaxone competitors."...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!